Page last updated: 2024-12-09

2-(3-pyridinyl)-4-thiophen-2-ylthiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(3-pyridinyl)-4-thiophen-2-ylthiazole, also known as **thiazole derivative** or **thiazole analog**, is a chemical compound with a unique structure containing a thiazole ring fused to a pyridine ring and a thiophene ring.

**Importance in Research:**

This compound is of significant interest to researchers due to its potential applications in various fields:

* **Pharmacology:**
* **Anti-cancer activity:** Thiazole derivatives have shown promising anti-cancer activity against various cancer cell lines, including leukemia, breast, and colon cancer. They can potentially interfere with cell proliferation and induce apoptosis (programmed cell death).
* **Anti-inflammatory activity:** Some thiazole derivatives exhibit anti-inflammatory properties, which could be beneficial in treating inflammatory diseases like arthritis.
* **Antimicrobial activity:** Thiazoles have been explored for their antibacterial and antifungal properties, potentially contributing to the development of new antibiotics and antifungals.
* **Neuroprotective activity:** Some thiazole compounds have shown potential in protecting neurons from damage caused by oxidative stress and neurodegenerative diseases like Alzheimer's and Parkinson's.

* **Materials Science:**
* **Organic electronics:** Thiazoles and their derivatives can act as building blocks for organic semiconductors and photovoltaic materials due to their unique electronic properties.

* **Agriculture:**
* **Herbicides and pesticides:** Thiazoles have been investigated for their potential use as herbicides and pesticides, offering alternatives to conventional chemical agents.

**Further Research:**

Ongoing research focuses on:

* **Synthesis and characterization:** Developing efficient and environmentally friendly methods to synthesize these compounds and understand their structural properties.
* **Biological activity evaluation:** Investigating the mechanisms of action and efficacy of thiazoles against various diseases.
* **Structure-activity relationship (SAR) studies:** Exploring how modifications to the thiazole molecule affect its biological activity to design more potent and specific compounds.
* **Clinical trials:** Testing the safety and efficacy of promising thiazole derivatives in human subjects.

Overall, 2-(3-pyridinyl)-4-thiophen-2-ylthiazole and its analogs represent a valuable class of compounds with potential applications in a variety of fields. Further research is crucial to unlocking their full potential and translating these findings into practical applications.

Cross-References

ID SourceID
PubMed CID2348844
CHEMBL ID1572708
CHEBI ID121220

Synonyms (14)

Synonym
ENAMINE_002702
MLS000098137
smr000061212
IDI1_007049
CHEBI:121220
HMS1401K18
2-pyridin-3-yl-4-thiophen-2-yl-1,3-thiazole
HMS2153E11
HMS3314K02
CHEMBL1572708
Q27209751
2-(3-pyridinyl)-4-thiophen-2-ylthiazole
Z48847419
AKOS034400990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thiazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains a N atom and one S atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency25.11890.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency26.85450.007215.758889.3584AID588342
Nrf2Homo sapiens (human)Potency11.22020.09208.222223.1093AID624171
ATAD5 protein, partialHomo sapiens (human)Potency12.58930.004110.890331.5287AID504467
Smad3Homo sapiens (human)Potency6.30960.00527.809829.0929AID588855
hypothetical protein, conservedTrypanosoma bruceiPotency3.98110.223911.245135.4813AID624173
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency12.58930.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency14.58100.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency7.30785.804836.130665.1308AID540253
mitogen-activated protein kinase 1Homo sapiens (human)Potency15.84890.039816.784239.8107AID995
snurportin-1Homo sapiens (human)Potency7.30785.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency7.30785.804816.996225.9290AID540253
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.84890.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]